-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Neumora Therapeutics, Raises Price Target to $5

Benzinga·07/16/2025 12:19:13
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and raises the price target from $4 to $5.